COMPANY OVERVIEW
TissUse GmbH, headquartered in Berlin, Germany, develops the HUMIMIC multi-organ-chip platform for systemic pharmacology studies. Founded in 2010 as a spin-out from the Technical University of Berlin by Prof. Uwe Marx, TissUse combines German precision engineering with advanced microphysiology to create human-relevant drug testing systems adopted by leading pharmaceutical companies.
HUMIMIC PLATFORM
- HUMIMIC Chip2: Two-organ interconnected system for gut-liver or skin-liver studies
- HUMIMIC Chip3: Three-organ platform adding pancreas or kidney
- HUMIMIC Chip4: Four-organ systemic model for comprehensive PK/PD
- On-Chip Micropumps: Proprietary peristaltic pumps for physiological blood flow
- Integrated Sensors: Real-time monitoring of oxygen, pH, and metabolites
KEY APPLICATIONS
- Systemic ADME-Tox profiling with multi-organ metabolism
- Repeated-dose toxicity studies (up to 28 days, regulatory-relevant)
- Skin-liver interactions for cosmetic and dermatological testing
- Tumor-immune system interactions for immuno-oncology
- Organ crosstalk studies for metabolic disease
REGULATORY PROGRESS
TissUse actively engages with EMA and FDA on regulatory acceptance pathways. Their platforms have been used in IND-enabling studies and are being evaluated for replacement of specific animal study requirements under the EU 3Rs framework.